Context Therapeutics Inc.

NASDAQ:CNTX

Biotechnology

Healthcare
$0.69 +2.93%

+$0.02 today

Market cap
$63.67M
Beta
1.61
P/E (TTM)
-1.5
EPS (TTM)
-$0.42
52W Low $0.56High $3.62

Volume 1.71M

Average 1.16M

CNTX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Context Therapeutics Inc.NASDAQ: CNTX

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables outflow grows to $0

Q1 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.

Context

  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Receivables vs competitors

How CNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
CNTX Competitors
Accounts Receivables for CNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IFRXInflaRx N.V.LTM Mar 2026€1.95M EUR+3826.6%—6648.5%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$1M USD+141.0%-18.7%14.0%
CNTBConnect Biopharma Holdings LimitedFY2025$776K USD+198.4%+512.8%1212.5%
MGNXMacroGenics, Inc.LTM Mar 2026$117K USD+103.5%-41.7%0.1%
CLNNClene Inc.LTM Mar 2026$157.88 USD-99.8%—0.1%
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD———
STTKShattuck Labs, Inc.LTM Mar 2026$0 USD——0.0%
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 USD——0.0%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$0 USD———
KLRSKalaris Therapeutics IncLTM Mar 2026$0 USD———
IMAImageneBio IncLTM Mar 2026$0 USD+100.0%——
Peer median (excluding CNTX) —+122.2%-18.7%0.1%

Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Depreciation & Amortization09.27K12.04K10.88K16.25K
Deferred Income Tax00000
Stock-Based Compensation511.08K976.44K1.08M841.87K1.33M
Change in Working Capital(2.22M)(277.52K)1.78M(3.48M)6.28M
Accounts Receivables00000
Inventory00000
Accounts Payables(866.01K)(787.89K)1.45M(946K)1.1M
Other Working Capital(1.36M)510.37K329.03K(2.53M)5.19M
Other Non-Cash Items3.37M578.52K51.97K14.79M2.11M
Operating Cash Flow(8.8M)(13.55M)(21.05M)(14.56M)(26.39M)
Capital Expenditures(250K)(536.84K)0(14.76M)(33.95K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities000(14.75M)(2M)
Investing Cash Flow(250K)(536.84K)0(14.76M)(2.03M)
Debt Repayment00000
Common Stock Issued53.41M(102.07K)0109.29M(15.27K)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow58.39M(102.07K)0109.29M(15.27K)
Effect of Forex Changes050.39K000
Net Change in Cash49.34M(14.14M)(21.05M)79.98M(28.43M)
Free Cash Flow(9.05M)(14.09M)(21.05M)(29.31M)(26.42M)

Context Therapeutics Inc.

NASDAQ:CNTX

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.